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INTRODUCTION
Micro- and nano-sized magnetic support is a recently
developed revolutionary technology for bioseparation,
especially for ligand fishing, protein, enzyme, DNA, RNA
and cell isolation or purification. Magnetic nanoparticles
(MPs) are referred to by various synonyms, such as
magnetic beads (MB) or micro- and nano-sized magnetic
beads. They are also called ferrofluids or magnetic fluids,
meaning colloidal suspensions of magnetic particles in a
liquid carrier. Generally, these particles are part of
nanotechnology, which can be defined as engineering of
functional systems on a molecular scale. It has the potential
to create many new materials and devices with a wide
range of applications across the biomedical, chemical,
electronic and mechanical fields.
Their superparamagnetic properties have opened prom-
ising new perspectives for their application in several areas.
The pioneering “medical” application in the treatment of
lymphatic nodes and metastases based on injecting “metal-
lic particles” preheated in a magnetic field was first
published by Gilchrist et al. in 1957 (1). Since then,
magnetic particles have been modified by coating with
antibodies, enzymes, proteins or specific ligands that enable
them to bind to other biologically active compounds or
receptors on the cell surface. In the last decade, magnetic
particles have been increasingly used as a promising
technique for a wide spectrum of biomedical applications.
The number of publications presenting original studies on
using magnetic beads is increasing year by year (Fig. 1).
The growing interest in the magnetic carrier is focused on
biochemistry, molecular biology and medical specialties.
Because of the superparamagnetic properties and micro-
and nano-dimensions, magnetic nanoparticles can be used
to isolate any target and linked to various manual and
automated applications (2–4). Innovative research has
produced a new application for magnetic nanoparticles
that carries an exciting biomedical and bioengineering
potential, for instance, cell molecule and nucleic acid
separation, immunoassays, pathogen detection, protein
purification, gen mutation analysis and magnetic-force-
based tissue engineering (5,6). Also, the interest in the
potential application of the magnetic technique in pharma-
cy is significantly growing. It is currently being recognised
that this magnetic nanotechnology could play an important
role in this area.
DRUG DISCOVERY
The process of drug discovery in the modern scientific
aspect is very complex. It integrates many disciplines,
including biotechnology, medicine and pharmacology. For
years, drug discovery has also focused on identification of
unknown biomolecular interactions with known targets. A
number of established methods are used in evaluating the
binding of ligands/drugs to receptors and proteins, such as
equilibrium dialysis, ultrafiltration, ultracentrifugation, bio-
affinity chromatography and other spectroscopic methods.
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(SPR) are the two most popular recently technologies for
real-time biomolecule interaction analysis. Because of the
different modifications of multifunctional surface of the
magnetic particles, these approaches are practically useful
in this area.
The objective of the recent study was to adapt
immobilized human serum albumin (HSA) onto the surface
of magnetic beads for the purpose of “ligand fishing” (3).
These beads correctly isolated a known binder from a
mixture of known compounds, and the whole experiment
was carried out manually using a magnet and automatically
using the Magtration System. Furthermore, the magnetic
separation technique was extended to the protein-ligand
and protein–protein interaction using magnetic beads with
immobilized heat-shock protein 90α (Hsp90α)( 2). The
advantage of this system is that the Hsp90α-coated
magnetic beads can isolate interacting partners (ligand
and proteins) from complex mixtures and cellular extracts
(e.g. from KU-812 cells) in less than 15 min, unlike co-
immunoprecipitation methods, which take several hours to
recover the protein of interest. Presently, the extension of
the magnetic beads method to multiple complex cellular
extracts and complex plant extracts is being investigated.
The most recent study demonstrates that ligand fishing
based on biological functionalised MB is an effective and
convenient way to identify and isolate bioactive small
molecules from botanical extracts (Camptotheca acuminata
and Dioscorea nipponica), and the process has a significant
structure specifity (7,8).
Using a similar concept, protein-coated magnetic beads
were used as a tool for a rapid drug-protein binding study
(4). Knowledge of serum protein binding behaviour as a
significant component of blood is very important for the
rational use of drugs. An extensive understanding of the
ligand/drug-protein interaction may be of special impor-
tance for the modelling of pharmacokinetics, including
possible drug–drug interaction. In this context, magnetic
beads with immobilized HSA have been successfully used to
determine the affinity of known drugs for the protein (4).
Moreover, the preliminary competition experiments suggest
that protein-coated magnetic beads can be employed in
drug–drug interaction studies. However, the validation of
the proposed method is being investigated.
DRUG DELIVERY
Advances in many fields are converging to make the
commercialisation of advanced drug delivery concepts
possible (6). Innovative drug delivery devices should protect
labile active ingredients, precisely control drug release
kinetics, and minimise the release of the drug to non-
target sites.
The major advantage of ferromagnetic materials (Fe3O4)
and maghemite (γ-Fe2O3) over other materials with a high
magnetic moment is the possibility for in vivo applications (6).
Othermaterials,suchascobaltandnickel,cancauseoxidative
stress or long-term changes in enzyme kinetics. Hence, their
use should be limited in biomedical applications.
The use of magnetic nanoparticles as drug carriers in
targeted therapy provides huge opportunities in cancer
treatment, as the use of such carriers considerably reduces
the side effects of conventional chemotherapy. For drug
targeting, they are able to cumulate in desired locations
within the body with the help of a magnet. In 1978,
magnetic particles were first applied as a new class of drug
target. The tool was based on albumin microspheres with
entrapped Fe3O4 and doxorubicin. A novel carrier system
allowed for the accumulation of local chemotherapeutic
agent which was comparable to that achieved by the
administration of a 100-fold higher dose of the drug. Other
results indicate that the new targeting system of specific
drug delivery based on the “magnetic granules” might be
useful for local chemotherapy of oesophageal cancer in
rabbits administered via the oral route. Another interesting
application has utilised iron oxide nanoparticles covered by
starch polymers which makes the ferrofluids tolerable to
healthy tissues and cells. The time-dependent distribution
of the ferrofluids as a carrier for mitoxantrone within the
body was already investigated by labelling the nanoparticles
with radioactive isotope
59Fe (9). Also, electron microscope
investigations have shown that the ferrofluids do not only
concentrate in the cancer tissue but also penetrate into the
tumour cells.
The use of magnetic beads can significantly improve
hyperthermia cancer treatment. This therapy involves
raising the temperature of the target tissue to 43–46°C,
which increases its sensitivity to chemo- and radiotherapy
and may additionally stimulate activities of the host
immune system (10). Magnetic hyperthermia relies on the
introduction of ferro- or superparamagnetic particles into
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Fig. 1 The number of publications on the subject “Magnetic Beads” and
“Biochemistry and Molecular Biology, Medicine or Pharmacology, Toxicol-
ogy and Pharmaceutics” identified by Scopus (http://www.scopus.com/
home.url).
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energy is converted to thermal energy, which destroys
cancer tissues. Cancer-specific binding agents could include
antibodies, hormones, and other exo- and endogenous
substances. Attaching these agents, such as estrogen,
testosterone, and thyroid hormones, to magnetic nano-
particles has promising implications for magnetic fluid
hyperthermia treatment (MFH) of breast, prostate, and
thyroid cancer, respectively. Recently, monoclonal anti-
bodies to cancer cell surface antigens and modified viruses
that are able to bind with receptors on certain types of
cancer cells are being considered as novel potentially
binding agents coupled with magnetic particles. This tool
could be successfully used to locate cancer cells and deliver
chemotherapeutics directly to “cancer” location at elevated
temperatures.
A recent study published in Nature Nanotechnology reports
for the first time target aerosol delivery to the lung achieved
with aerosol droplets comprising superparamagnetic iron
oxide nanoparticles in combination with a target-directed
magnetic gradient field (11). Standard therapy with
cytotoxic drugs relies on the attainment of high drug
concentrations at the affected site, which is particularly
difficult in lung cancer (12). Thus, the novel and promising
method could be used to accumulate effective drug doses in
the affected lung areas and reduce undesirable effects. As
the in vitro study has illustrated the enhanced deposition of
high aspect ratio aerosols in the small airways using
magnetic field alignment, in a recent study, computational
fluid dynamics (CFD) simulations of magnetic aerosol
transport and deposition were conducted and compared
with the experimental findings (13). The demonstrated
excellent predictive power of the CFD model suggests that
inhalation delivery systems for in vivo selective respiratory
drug delivery can potentially be designed based on
observable magnetic and aerosol properties. The magnetic
targeted carriers (MTCs) have also been proposed and
developed to submicron-sized ferromagnetic particle prep-
aration containing relaxant drugs for local anesthesia and
improve targeting efficiency of pharmaceutical agents in the
treatment of carcinoma in rabbits (14).
Furthermore, recent clinical research shows that expo-
sure to iron nanoparticles increases endothelial cell perme-
ability caused by oxidative stress resulting from reactive
oxygen material (15). This phenomenon offers fascinating
opportunities for magnetic beads in personalised cancer
therapies.
CELL AND GENE THERAPY
Cell therapies are based on biological agents involving stem
cells or immune cells to be administered to patients for the
treatment of several diseases. The development of nonin-
vasive imaging techniques to monitor cell migration to
target tissues is of particular importance for cell-based
therapies. Monitoring magnetically labeled cells with
magnetic resonance imaging (MRI) has increased our
understanding of cellular migration and the pathophysiol-
ogy of diseases in experimental models and in vivo (16).
Recently, the potential clinical application of anionic
magnetic nanoparticles (AMNPs), ultrasmall paramagnetic
iron oxides (USPIOs) and superparamagnetic iron oxide
nanoparticles (SPIONs) has been demonstrated to visualise
cell migration during MRI monitoring of cellular therapies
(17,18). These agents cause a strong source of contrast
resulting from the increased differences in signal intensities
that each tissue produces in response to the applied radio
frequency pulses. Recent reports describe utilising small
contrast agents to track the migration of stem cells, immune
cells and other cells in numerous animal models of
malignancy, angiogenesis, ischaemia, organ failure, auto-
immune diseases and transplantation rejection (17). Track-
ing labelled cells using magnetic particles with MRI has
clearly demonstrated its usefulness in evaluating promising
cell-based therapies in preclinical models. However, their
translation to the clinical practice is being considered in the
near future (17).
The successful magnetic microsphere delivery approach
has been used in gene therapy to reduce the incidence of
adverse events, particularly in the case of viral and
retroviral vectors. Gene therapy is a potential therapeutic
tool that requires effective gene delivery. However, the
most common methods for delivering genes into cell is
associated with two potential dangers: oncogenesis and
inflammation. This therapeutic strategy, based on magnetic
technology, is an alternative method of viral gene delivery.
Moreover, magnetic reporter genes inserted into cells result
in expression of iron storage proteins that can be detected
by MRI. The novel approach for improving viral DNA
delivery system has been studied using modified cationic
chitosan-coated iron oxide nanoparticles (Nac-6-IOPs)( 19).
The advantage of this system is the reduction of viral doses,
time of infection and viral side effects. In another study, the
enhancement of non-viral gene transfer was achieved by
Lipofectamine™ 2000 or cationic lipid 67 (GL67)/plasmid
DNA (pDNA) liposome complexes coupled with super-
paramagnetic particles (20). A novel non-viral delivery
system based on a polyethylenimine coated on the surface
of bacterial magnetic nanoparticles (BMPs) has been
developed with high transfection efficiency and low toxicity,
which presents an attractive strategy for gene therapy and
DNA vaccination (21).
The nanoparticle technology is highly novel and offers
many possibilities for future development. Although the
particles possess useful properties for biomedical applica-
482 Marszałłtions, they also carry potential health risks. Generally, the
nanomaterials pose many new questions on risk assessment
that are not yet completely answered. Thus, a reliable risk
assessment related to human health and environment and
safety evaluation of these materials should be performed for
all in vivo studies. In 2007, the Food and Drug Administra-
tion issued a report to consider developing guidance for
regulation of products that contain nanoscale materials (22).
Open Access This article is distributed under the terms of
the Creative Commons Attribution Noncommercial Li-
cense which permits any noncommercial use, distribution,
and reproduction in any medium, provided the original
author(s) and source are credited.
REFERENCES
1. Gilchrist RD, Medal R, Shorey WD, Hanselman RC, Parrott JC,
Taylor CB. Selective inductive heating of lymph nodes. Ann Surg.
1957;4:596–606.
2. Marszałł MP, Moaddel R, Kole S, Gandhari M, Bernier M,
Wainer IW. Ligand and protein fishing with heat shock protein 90
coated magnetic beads. Anal Chem. 2008;80:7571–5.
3. Moaddel R, Marszałł MP, Bighi F, Yang Q, Duan X, Wainer IW.
Automated ligand fishing using human serum albumin-coated
magnetic beads. Anal Chem. 2007;79:5414–7.
4. Marszałł MP, Buciński A. A protein-coated magnetic beads as a
tool for the rapid drug–protein binding study. J Pharm Biomed
Anal. 2010;52:420–4.
5. Edelstein ML, Abedi MR, Wixon J. Gene therapy clinical trials
worldwide to 2007—an update. J Gene Med. 2007;9:833–42.
6. Corchero JL, Villaverde A. Biomedical applications of distally
controlled magnetic nanoparticles. Trends Biotechnol. 2009;
27:468–76.
7. Marszałł MP, Buciński A, Kruszewski S, Ziomkowska B. A new
approach to determine camptothecin and its analogues affinity
to human serum albumin. J Pharm Sci. 2010. doi:10.1002/jps.
22318.
8. Qing L-S, Xue Y, Zheng Y, Xiong J, Liao X, Ding L-S, et al.
Ligand fishing from Dioscorea nipponica extract using human
serum albumin functionalized magnetic nanoparticles. J Chroma-
togr A. 2010;1217:4663–8.
9. Alexiou Ch, Schmid RJ, Jurgons R, Kremer M, Wanner G,
Bergemann Ch, et al. Targeting cancer cells: magnetic nano-
particles as drug carriers. Eur Biophys J. 2006;35:446–50.
10. Ang KL, Venkatraman S, Ramanujan RV. Magnetic PNIPA
hydrogels for hyperthermia applications in cancer therapy. Mater
Sci Eng C. 2007;27:347–51.
11. Dames P, Gleich B, Flemmer A, Hajek K, Seidl N, Wiekhorst F, et
al. Targeted delivery of magnetic aerosol droplets to the lung. Nat
Nanotechnol. 2007;2:495–9.
12. Plank Ch. Nanomagnetosols: magnetism opens up new perspec-
tives for targeted aerosol delivery to the lung. Trends Biotechnol.
2008;26:59–63.
13. Xie Y, Zeng P, Siegel RA, Wiedmann TS, Hammer BE, Longest
PW. Magnetic deposition of aerosols composed of aggregated
superparamagnetic nanoparticles. Pharm Res. 2010;27:855–
65.
14. Alexiou C, Jurgons R, Schmid R, Hilpert A, Bergemann Ch,
Parak F, et al. In vitro and in vivo investigations of targeted
chemotherapy with magnetic nanoparticles. J Magn Magn Mater.
2005;293:389–93.
15. Apopa PL, Qian Y, Shao R, Guo NL, Schwegler-Berry D,
Pacurari M, et al. Part Fibre Toxicol. 2009;6:1–14.
16. Budde MD, Frank JA. Magnetic tagging of therapeutic cells for
MRI. J Nucl Med. 2009;50:171–4.
17. Wilhelm C, Gazeau F. Universal cell labelling with anionic
magnetic nanoparticles. Biomaterials. 2008;29:3161–74.
18. Modo M, Hoehn M, Bulte JW. Cellular MR imaging. Mol
Imaging. 2005;4:143–64.
19. Bhattarai SR, Kim SY, Jang KY, Lee KC, Yi HK, Lee DY, et al.
Laboratory formulated magnetic nanoparticles for enhancement
of viral gene expression in suspension cell line. J Virol Methods.
2008;147:213–8.
20. Xenariou S, Griesenbach U, Ferrari S, Dean P, Scheule RK,
Cheng SH, et al. Using magnetic forces to enhance non-viral gene
transfer to airway epithelium in vivo. Gene Ther. 2006;13:1545–
52.
21. Xiang L, Bin W, Huali J, Wei J, Jiesheng T, Feng G, et al.
Bacterial magnetic particles (BMPs)–PEI as a novel and efficient
non-viral gene delivery system. J Gene Med. 2007;9:679–90.
22. Nanotechnology Task Force Report. 2007, http://www.fda.gov/
ScienceResearch/SpecialTopics/Nanotechnology/Nanotechnology
TaskForceReport2007/default.htm.
Application of Magnetic Nanoparticles in Pharmaceutical Sciences 483